Back to Authors

Eggenberger, Eric R

Mayo Clinic

From the Departments of Ophthalmology (J.J.C., M.T.B.), Neurology (J.J.C., E.P.F., M.T.B., J.J., D.D., A.S.L.C., B.G.W., A.M., J.-M.T., V.A.L., C.F.L., A.K., S.J.P.), Laboratory Medicine and Pathology (E.P.F., J.J., D.D, J.P.F., A.M., V.A.L., S.J.P.), and

Citations 8

Central Retinal Artery Occlusion Associated with Takayasu Arteritis

Diagnostics | June 24, 2024 | Volume: 14 | Issue: 13 | Pages: 1329

10.3390/diagnostics14131329 | PMID 39001220

Takayasu arteritis is a chronic inflammatory vasculitis with granulomatous panarteritis particularly impacting large vessels including the aorta and its branches, especially the subclavian arteries, with clinical manifestation dependent on the involved artery. Sequelae of the active disease vary, including stenosis, occlusions, or aneurysmal dilatations of the large vessels. The prevalence of Takayasu arteritis is higher in the Asian population and in Japan, but quite low in the United States, varying from 0.9–8.4 per million people. Ocular manifestations are rare and lead to a delay in diagnosis and appropriate treatment. Ocular manifestations include Takayasu retinopathy, anterior ischemic optic neuropathy (AION), retinal artery occlusion (RAO) and retinal vein occlusion (RVO). We present two cases in which central retinal artery occlusion (CRAO) was associated with Takayasu arteritis. CRAO is an ophthalmic emergency with an incidence of 1.9 per 100,000 person years in the United States; only 5% of cases are arteritic, which can be observed with inflammatory vasculitides secondary to the formation of immune deposits.
Frequency of Asymptomatic Optic Nerve Enhancement in a Large Retrospective Cohort of Patients With Aquaporin-4+ NMOSD

Neurology | June 13, 2022 | Volume: 99 | Issue: 8 | Pages: No page available

10.1212/wnl.0000000000200838 | PMID 35697504

Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

JAMA Neurology | April 4, 2022 | Volume: 79 | Issue: 5 | Pages: 518

10.1001/jamaneurol.2022.0489 | PMID 35377395

The Outpatient Approach to Dizziness

Seminars in Neurology | November 26, 2021 | Volume: 41 | Issue: 06 | Pages: 771-780

10.1055/s-0041-1726369 | PMID 34826878

AbstractThe evaluation of the dizzy patient is complicated by many common pitfalls. The patient's description of symptoms and the standard neurologic examination are often nonspecific or unrevealing, and neuroimaging is most often normal. Over the past several years, research has demonstrated that a refocusing of history taking results in more reliable and diagnostically helpful information. This can guide a targeted expansion of the exam, often with an emphasis on eye movements.
Teaching Video NeuroImages: Periodic Alternating Nystagmus in Paraneoplastic KLHL11 Rhomboencephalitis

Neurology | May 24, 2021 | Volume: 96 | Issue: 21 | Pages: No page available

10.1212/wnl.0000000000011711 | PMID 33589533

Neuro‐Ophthalmological Findings in Early Fatal Familial Insomnia

Annals of Neurology | January 2, 2021 | Volume: 89 | Issue: 4 | Pages: 823-827

10.1002/ana.26008 | PMID 33386648

Fatal familial insomnia (FFI) is a rare inherited prion disease characterized by sleep, autonomic, and motor disturbances. Neuro‐ophthalmological abnormalities have been reported at the onset of disease, although not further characterized. We analyzed video recordings of eye movements of 6 patients with FFI from 3 unrelated kindreds, seen within 6 months from the onset of illness. Excessive saccadic intrusions were the most prominent findings. In patients with severe insomnia, striking saccadic intrusions are an early diagnostic clue for FFI. The fact that the thalamus is the first structure affected in FFI also suggests its role in the control of steady fixation. ANN NEUROL 2021;89:823–827
Toward allele-specific targeting therapy and pharmacodynamic marker for spinocerebellar ataxia type 3

Science Translational Medicine | October 21, 2020 | Volume: 12 | Issue: 566 | Pages: No page available

10.1126/scitranslmed.abb7086 | PMID 33087504

PolyQ ATXN3 is a pharmacodynamic marker for SCA3, and a SNP associated with the expanded allele may serve to specifically target mutant ATXN3 .
Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder

Neurology | June 18, 2020 | Volume: 95 | Issue: 2 | Pages: No page available

10.1212/wnl.0000000000009758 | PMID 32554760